RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Our drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types. We hold an exclusive license from Columbia University for its RyR technology based on the research of our founder, Dr. Andrew Marks. RyCarma’s lead candidate, ARM210, is in development for the treatment of heart failure and ryanodine receptor 1-related myopathies (RYR1-RM).
Investors 2
| Date | Name | Website |
| 19.05.2025 | Forbion | forbion.co... |
| 03.02.2025 | Pontifax V... | pontifax.c... |